Background
==========

Recent reports on new multidrug resistant bacteria from India (NDM-producing strains) show that adequate and rapid screening methods for antibiotic resistance due to those enzymes are crucially needed \[[@b1-medscimonit-18-9-mt71]--[@b3-medscimonit-18-9-mt71]\].

Beta-lactam antibiotics hydrolyzing enzymes, called beta-lactamases, have been known since the early 1950s and have been well-characterized since the 1980s \[[@b4-medscimonit-18-9-mt71], [@b5-medscimonit-18-9-mt71]\]. They are divided into 2 main groups based on description of their activity -- Serine-beta-lactamases (Ambler class A, C and D) and metallo-beta-lactamases (Ambler class B). Enzymes of actual concern mostly derive from these 2 classes.

Ambler Class A extended-spectrum-beta-lactamases (ESBL) with a substrate specificity up to 3^rd^ and 4^th^ generation cephalosporins are a major cause of antibiotic resistance in *Enterobacteriaceae* and their presence is often linked to additional antibiotic resistance, such as fluoroquinolones and cotrimoxazole \[[@b5-medscimonit-18-9-mt71]--[@b9-medscimonit-18-9-mt71]\]. *Escherichia coli* and *Klebsiella pneumoniae* are the most common pathogens producing ESBLs and are ranking among the 3 most common pathogens causing nosocomial infections, predominantly urinary tract infections \[[@b7-medscimonit-18-9-mt71],[@b9-medscimonit-18-9-mt71]\].

Ambler Class B metallo-Beta-Lactamases (MBLs) are a chief cause of antibiotic resistance in nonfermenting bacteria such as *Pseudomonas aeruginosa*, conferring resistance to all beta-lactams, including carbapenems \[[@b5-medscimonit-18-9-mt71],[@b10-medscimonit-18-9-mt71]\]. MBL producing *P. aeruginosa* constitute a severe clinical threat since they often occur as multidrug-resistant pathogens in immunocompromised patients, as well as in those with cystic fibrosis \[[@b10-medscimonit-18-9-mt71],[@b11-medscimonit-18-9-mt71]\].

*E. coli, K. pneumoniae* and *P. aeruginosa* are ranked among the 3 most common pathogens causing nosocomial infections, and their antibiotic resistance due to ESBLs and MBLs has become a worldwide problem \[[@b6-medscimonit-18-9-mt71],[@b11-medscimonit-18-9-mt71],[@b12-medscimonit-18-9-mt71]\]. Thus, diagnostic laboratories depend on systems suitable for rapid and exact identification of those resistance factors.

Currently, systems for the detection of ESBL- and MBL-producing bacteria are mostly phenotypical methods \[[@b13-medscimonit-18-9-mt71]\]. As a function of these methods, another incubation period and special growth media are necessary, leading to increased costs and time span until a specific antibiotic therapy can be initiated.

Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) has already proven to be a powerful tool for species identification in microbiological laboratories \[[@b14-medscimonit-18-9-mt71]--[@b20-medscimonit-18-9-mt71]\]. Further studies attempted to evaluate the performance of MALDI-TOF MS in the detection of antibiotic-resistant strains, such as Methicillin-resistant *Staphylococcus aureus* (MRSA), but showed unsatisfactory results \[[@b21-medscimonit-18-9-mt71],[@b22-medscimonit-18-9-mt71]\]. Subsequent publications showed the detection of ESBL-primer extensions by MALDI-TOF MS \[[@b23-medscimonit-18-9-mt71]\], revealed spectral distinctions among carbapenemase-gene harboring and non-harboring *Bacteroides fragilis*\[[@b24-medscimonit-18-9-mt71],[@b25-medscimonit-18-9-mt71]\], and proved that MALDI-TOF MS can detect degradation products of antibiotics due to hydrolysis by beta-lactamases \[[@b26-medscimonit-18-9-mt71]--[@b28-medscimonit-18-9-mt71]\]. Most of the aforementioned protocols require further steps of incubation with antibiotics or primer extension prior to MALDI-TOF MS analysis, necessitating a longer time span compared to usual mass spectrometric species identification.

Camara et al were the first to demonstrate that MALDI-TOF MS can distinguish between wild-type and AmpC-plasmid-transformed strains of *E. coli*\[[@b29-medscimonit-18-9-mt71]\] in higher mass ranges -- up to 30 kDalton (Da) -- than actually recommended for species identification (ie, \>20 kDa) \[[@b15-medscimonit-18-9-mt71],[@b17-medscimonit-18-9-mt71]\]. The aim of the present study was to evaluate the performance of MALDI-TOF MS in the discrimination among ESBL-producing or MBL-producing and the nonproducing clinical isolates of *E. coli*, *K. pneumoniae* and *P. aeruginosa,* even in a mass range usual for species identification, in order to integrate the screening for resistance factors into routine species identification by MALDI-TOF MS.

Material and Methods
====================

Chemicals
---------

α-cyano-4-hydroxycinnamic acid was purchased from Bruker Daltonics, Bremen, Germany; trifluoroacetic acid (TFA) was from Merck, Darmstadt, Germany; and acetonitrile was from Sigma, Taufkirchen, Germany. Deionized water was used in all experiments. Columbia agar base and the other media used were purchased from Oxoid, Basingstoke, United Kingdom \[[@b20-medscimonit-18-9-mt71]\].

Bacterial strains, culture, phenotypic and resistance identification
--------------------------------------------------------------------

A total of 76 clinical isolates of *Enterobacteriaceae* and *P. aeruginosa* were used in this study. Nineteen strains of *E. coli*, including 9 ESBL-producing strains, were recovered from urine (n=14), sputum (n=3), pharyngeal smear (n=1) and abscesses (n=1). Nineteen strains of *K. pneumoniae*, including 12 ESBL-producing strains, were recovered from urine (n=12), wound swabs (n=2), blood culture (n=1), bronchial lavage (n=1), and renal puncture (n=1). The 38 isolates of *P. aeruginosa,* of which 13 tested positive for MBL production, were recovered from tracheal secretions (n=13), wound swabs (n=10), sputum (n=6), bronchial lavages (n=4), vaginal swabs (n=2), urine (n=2), bile (n=2), and pleura puncture (n=1).

All isolates were subcultured at 37°C on 5% sheep blood agar. Biochemical identification was performed by ID 32 E and ID 32 GN systems (bioMérieux, Lyon, France), respectively. ESBL- and MBL-producing strains were identified by appropriate Etest (AB bioMérieux, Solna, Sweden). For further analysis, the strains were stored at −80°C in Cryobank preservation tubes (Mast Diagnostica GmbH, Reinfeld, Germany).

Standard samples
----------------

The following reference strains were used to validate appropriate species affiliation of the clinical samples: *E. coli* ATCC 25922, *K. pneumoniae* 911 (a strain from an interlaboratory test in Germany), and *P. aeruginosa* ATCC 27853.

Sample preparation for MALDI-TOF MS
-----------------------------------

The strains were cultivated on 5% sheep blood agar plates and incubated for 24 h at 37°C. Ten to 15 individual colonies were transferred into deionized water and washed twice. Afterwards, the sediment was dissolved in 50 μl 80% TFA and incubated for 10 min at ambient temperature. Then 150 μl of deionized water was added to reduce TFA-activity, followed by 200 μl acetonitrile. Thereafter, the samples were centrifuged at 13,000 rpm for 2 min; the supernatant was transferred into a new 1.5 ml Eppendorf tube, and then stored at −20°C. For further analysis, the thawed samples were dried in a vacuum centrifuge. The pellet was dissolved in 20 μl of 2.5% TFA/50% acetonitrile. One microliter of each sample was pipetted 5 times on a stainless steel MALDI target plate. After air drying, each sample was overlaid with 1 microliter of matrix (α-cyano-4-hydroxycinnamic acid as a saturated solution in 2.5% TFA/50% acetonitrile). The matrix/sample spots were crystallized by air drying \[[@b20-medscimonit-18-9-mt71]\].

MALDI-TOF MS parameters and data analysis
-----------------------------------------

The mass spectra were acquired with an Autoflex II (Bruker Daltonics, Bremen, Germany) MALDI-TOF mass spectrometer with a nitrogen laser (λ=337nm) operated in the positive linear mode (delay 350 ns, voltage 20 kV; mass over charge ratio (m/z) ranging from 2,000 to 12,000) under control of FlexControl software (version 2.4; Bruker Daltonics). Each spectrum was obtained by averaging 500 laser shots acquired in automatic mode at the minimum laser power necessary for ionization of the samples. The calibration strain for each MALDI-TOF optical measurement was *E. coli* GSM 2163 from New England BioLabs. Data files were transferred to FlexAnalysis software (version 2.4; Bruker Daltonics) for automated peak extraction \[[@b20-medscimonit-18-9-mt71]\]. With this software, 50 peaks were automatically labeled in each spectrum according to their appearance above the background (threshold ratio 1.5). Correct labeling was controlled manually. Peak lists containing masses and intensities were exported as Excel files \[[@b20-medscimonit-18-9-mt71]\].

Cluster formation of the mass peaks
-----------------------------------

In order to refine spectra accuracy, peak lists were aligned for mass drift adjustment \[[@b20-medscimonit-18-9-mt71]\]. Briefly, a mass-dependent size of the mass window was used according to window size = size~abs~ + (size~rel~ \* peak mass) with size~abs~ =0.8 m/z and size~rel~ =0.001. Thus, for each bacterial species we created a mean spectrum containing common m/z values. All spectra obtained for this species were aligned individually to the peaks of the mean spectrum by linear mass adjustment of the peaks \[[@b30-medscimonit-18-9-mt71]\]. Subsequently, peak clusters were formed which contained all peaks originating from different individual spectra but occurring in the same window. All peaks assigned to 1 cluster are represented by the respective mean cluster mass. This procedure represents the basis of the mass spectrometric approach.

Species identification and classification
-----------------------------------------

For identification to the species level, similarity analysis between peak lists was carried out by using a hierarchical clustering procedure performed with MatLab software (Version 7.10.0.499; The Math-Works Inc., Natick, MA). Pair-wise comparison of the spectra determined the similarity between the latter by counting the number of clusters to which the 2 spectra contributed. By this procedure, a symmetric matrix of pair-wise similarities (peak mass-based similarity matrix) was formed. In addition, a similarity matrix (σ~i,j~), which considers peak masses and differences in the peak intensities, was calculated according to the following equation:

σ

i

,

j

=

∑

k

\[

1

\-

(

w

i

k

\-

w

j

k

w

i

k

\+

w

j

k

)

2

\]

The similarity of samples *i* and *j* was obtained over all clusters *k* contributing to either sample *i* or sample *j.****w***^k^~i~ represents the intensity of peak *i* in spectrum *k.*

Distance matrices (δ~i,j~) were calculated from normalized similarity matrices according to the following equation:
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Dendrograms were calculated on the basis of the distance matrices by using a complete linkage function.

In order to discriminate between beta-lactamase producing and non-producing strains within a species, mass spectra were classified using the support vector machine (SVM) tool implemented in the Bioinformatic toolbox of MatLab. This software, which features an efficient 2-class classification, enables the user to define a number of parameters and to select from a choice of built-in kernel functions, including a radial basis function and a polynomial kernel (of a given degree). The SVM-algorithm was trained with a set of spectra of bacteria of known identity. An error estimate of the class prediction was carried out by calculation of a 10-fold cross-validation error for the training group. For this purpose, the training set was first divided into 10 subsets of equal size. Sequentially, 1 subset was tested by using the classifier trained on the remaining 9 subsets. Thus, each probe of the training set was predicted once. The cross-validation accuracy is the percentage of data which were correctly classified \[[@b20-medscimonit-18-9-mt71]\].

Results
=======

In the mass spectra of the studied bacterial species the majority of the peaks were obtained below a mass over charge ratio (*m/z*) of 8,000; there were only few peaks above 10,000 and no peaks were observed above m/z 12,000 in a detection window up to m/z 20,000.

The reference and the collected strains of the 3 investigated species showed specific spectra which allowed a straightforward differentiation on the species level by similarity analysis ([Figure 1](#f1-medscimonit-18-9-mt71){ref-type="fig"}). In a second step, the spectra of the strains that WERE previously tested positive for ESBL- and MBL-production were compared to those that tested negative. There was no significant difference in a first visual comparison of the spectra ([Figure 2](#f2A-medscimonit-18-9-mt71){ref-type="fig"}). In order to establish an objective differentiation method, similarity analysis was performed to see whether the ESBL- or MBL-positive strains form separable clusters in comparison to the nonproducing strains. As shown in [Figure 3](#f3-medscimonit-18-9-mt71){ref-type="fig"} for *E. coli,* the ESBL-positive strains did not form an individual cluster, but scattered among the non-producing strains. Similar results were found for *K. pneumoniae* and *P. aeruginosa*.

Moreover, we used SVM-based algorithms for classification as a more sensitive attempt to discover distinctions in the spectral patterns of the antibiotic resistant strains. For each species, 2 classes were defined to which the antibiotic susceptible and the antibiotic resistant strains were assigned (eg, class1: ESBL-negative, class 2: ESBL-positive). The spectra were classified by the algorithm according to their designated class. The classification performance was tested by 10-fold cross-validation, achieving rates for correct classification up to 70%.

Discussion
==========

The correct classification rates achieved indicate that strains producing ESBLs and MBLs tend to form spectral patterns that are distinct from the nonproducing strains, but an accuracy of 70% does not allow a specific assignment of unknown samples to a single class. This indicates that neither statistical similarity analysis nor SVM-classification were able to reliably show significant distinctions in the spectral patterns of ESBL- or MBL-positive strains compared to the nonproducing strains of *E. coli*, *K. pneumoniae* and *P. aeruginosa* in terms of routine diagnostics.

Even randomly tested samples for peaks in higher mass-ranges up to 30,000 Da, as proposed by Camara et al. \[[@b29-medscimonit-18-9-mt71]\], showed no differences in the spectral patterns of the beta-lactamase-producing and the nonproducing strains (data not shown). The former success could be explained by a greatly increased protein synthesis level due to the *in vitro* plasmid-transformation, which cannot reflect the level of protein synthesis in clinical isolates already harboring those plasmids, and also partially by the utilization of a different matrix. Other studies with positive results \[[@b23-medscimonit-18-9-mt71],[@b26-medscimonit-18-9-mt71]--[@b28-medscimonit-18-9-mt71]\] used protocols that require different steps of pre-analytical preparation or incubation and did not aim to integrate the screening method into the routine species identification workflow.

Conclusions
===========

In conclusion, the MALDI-TOF MS protocol we used has potential to discriminate between beta-lactamase-negative strains of the species we investigated and strains producing ESBLs and MBLs, but it is not yet reliable enough for routine diagnostics. Thus, the integration of a dependable screening method for resistance factors into the routine species identification by MALDI-TOF MS could not satisfactorily be achieved with the protocol we used.

**Source of support:** Departmental sources

![Cluster analysis of the three investigated species' mass spectra. Spectra of the reference strains are indicated. The cluster formation shows the relationship between *E. coli* and *K. pneumoniae* as members of the family *Enterobacteriaceae* and the clear separation to the genus *P. aeruginosa*.](medscimonit-18-9-MT71-g001){#f1-medscimonit-18-9-mt71}

![MALDI-TOF mass spectra of nonproducing ESBL/MBL-negative strains. Mass spectra show no reproducible differences in the mass window we investigated.](medscimonit-18-9-MT71-g002ABC){#f2A-medscimonit-18-9-mt71}

![MALDI-TOF mass spectra of nonproducing corresponding ESBL/MBL-positive strains. Mass spectra show no reproducible differences in the mass window we investigated.](medscimonit-18-9-MT71-g002DEF){#f2B-medscimonit-18-9-mt71}

![Inner species similarity analysis among wild type and ESBL-positive (printed in bold) strains of *E. coli*. ESBL-positive *E. coli* strains formed no individual cluster but are scattered among the ESBL-negative strains, allowing no dependable discrimination.](medscimonit-18-9-MT71-g003){#f3-medscimonit-18-9-mt71}
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